Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click above link to view abstract, login required to view video.

Click to view ASCO 2024 Presentation for Trial 21-39.

Related Posts

Discover more posts like this.

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

Aug 21, 2024

Dr. Douglas Orr

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Aug 21, 2024

Dr. Minal Barve
See All Posts